The FDA, in a regulatory first, approved a targeted therapy based on a basket study. The move, which expanded the indications for the BRAF inhibitor vemurafenib to include Erdheim–Chester disease, points to a new approval pathway for drugs that treat rare cancers.
from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2CPf6DR
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου